Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 97

1.

Cost-effectiveness of laboratory monitoring in sub-Saharan Africa: a review of the current literature.

Walensky RP, Ciaranello AL, Park JE, Freedberg KA.

Clin Infect Dis. 2010 Jul 1;51(1):85-92. doi: 10.1086/653119. Review.

PMID:
20482371
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Economic evaluation of ART in resource-limited countries.

Loubiere S, Meiners C, Sloan C, Freedberg KA, Yazdanpanah Y.

Curr Opin HIV AIDS. 2010 May;5(3):225-31. doi: 10.1097/COH.0b013e3283384a9d. Review.

PMID:
20539078
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Monitoring of HIV viral load, CD4 cell count, and clinical assessment versus clinical monitoring alone for antiretroviral therapy in low-resource settings (Stratall ANRS 12110/ESTHER): a cost-effectiveness analysis.

Boyer S, March L, Kouanfack C, Laborde-Balen G, Marino P, Aghokeng AF, Mpoudi-Ngole E, Koulla-Shiro S, Delaporte E, Carrieri MP, Spire B, Laurent C, Moatti JP; Stratall ANRS 12110/ESTHER Study Group.

Lancet Infect Dis. 2013 Jul;13(7):577-86. doi: 10.1016/S1473-3099(13)70073-2. Epub 2013 Apr 18.

PMID:
23602084
[PubMed - indexed for MEDLINE]
4.

Cost-effectiveness of laboratory monitoring for management of HIV treatment in sub-Saharan Africa: a model-based analysis.

Hamers RL, Sawyer AW, Tuohy M, Stevens WS, Rinke de Wit TF, Hill AM; ART-A Consortium.

AIDS. 2012 Aug 24;26(13):1663-72.

PMID:
22695297
[PubMed - indexed for MEDLINE]
5.

Optimal frequency of CD4 cell count and HIV RNA monitoring prior to initiation of antiretroviral therapy in HIV-infected patients.

Kimmel AD, Goldie SJ, Walensky RP, Losina E, Weinstein MC, Paltiel AD, Zhang H, Freedberg KA; Cost-Effectiveness of Preventing AIDS Complications Investigators.

Antivir Ther. 2005;10(1):41-52.

PMID:
15751762
[PubMed - indexed for MEDLINE]
6.

Cost-effectiveness of routine and low-cost CD4 T-cell count compared with WHO clinical staging of HIV to guide initiation of antiretroviral therapy in resource-limited settings.

Athan E, O'Brien DP, Legood R.

AIDS. 2010 Jul 31;24(12):1887-95. doi: 10.1097/QAD.0b013e32833b25ed.

PMID:
20543661
[PubMed - indexed for MEDLINE]
7.

Alternative antiretroviral monitoring strategies for HIV-infected patients in east Africa: opportunities to save more lives?

Braithwaite RS, Nucifora KA, Yiannoutsos CT, Musick B, Kimaiyo S, Diero L, Bacon MC, Wools-Kaloustian K.

J Int AIDS Soc. 2011 Jul 30;14:38. doi: 10.1186/1758-2652-14-38.

PMID:
21801434
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Challenges in implementing HIV laboratory monitoring in resource-constrained settings: how to do more with less.

Bélec L, Bonn JP.

Future Microbiol. 2011 Nov;6(11):1251-60. doi: 10.2217/fmb.11.121. Review.

PMID:
22082287
[PubMed - indexed for MEDLINE]
9.

Monitoring of highly active antiretroviral therapy in HIV infection.

Walker AS, Gibb DM.

Curr Opin Infect Dis. 2011 Feb;24(1):27-33. doi: 10.1097/QCO.0b013e3283423e0e. Review.

PMID:
21150591
[PubMed - indexed for MEDLINE]
10.

Clinical impact and cost of laboratory monitoring need review even in resource-rich setting.

Sayana S, Javanbakht M, Weinstein M, Khanlou H.

J Acquir Immune Defic Syndr. 2011 Mar 1;56(3):e97-8. doi: 10.1097/QAI.0b013e31820472e8. No abstract available.

PMID:
21317583
[PubMed - indexed for MEDLINE]
11.

Cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, lopinavir-naive, protease inhibitor-resistant, HIV-infected adults in Belgium, Italy, Sweden and the UK.

Moeremans K, Hemmett L, Hjelmgren J, Allegri G, Smets E.

Pharmacoeconomics. 2010;28 Suppl 1:147-67. doi: 10.2165/11587500-000000000-00000.

PMID:
21182349
[PubMed - indexed for MEDLINE]
12.

Cost effectiveness of darunavir/ritonavir 600/100 mg bid in protease inhibitor-experienced, HIV-1-infected adults in Belgium, Italy, Sweden and the UK.

Moeremans K, Annemans L, Löthgren M, Allegri G, Wyffels V, Hemmet L, Caekelbergh K, Smets E.

Pharmacoeconomics. 2010;28 Suppl 1:107-28. doi: 10.2165/11587480-000000000-00000.

PMID:
21182347
[PubMed - indexed for MEDLINE]
13.

Cost-effectiveness of point-of-care viral load monitoring of antiretroviral therapy in resource-limited settings: mathematical modelling study.

Estill J, Egger M, Blaser N, Vizcaya LS, Garone D, Wood R, Campbell J, Hallett TB, Keiser O; IeDEA Southern Africa.

AIDS. 2013 Jun 1;27(9):1483-92. doi: 10.1097/QAD.0b013e328360a4e5.

PMID:
23462219
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

When to initiate highly active antiretroviral therapy in sub-Saharan Africa? A South African cost-effectiveness study.

Badri M, Cleary S, Maartens G, Pitt J, Bekker LG, Orrell C, Wood R.

Antivir Ther. 2006;11(1):63-72.

PMID:
16518961
[PubMed - indexed for MEDLINE]
15.

Prognostic value of virological and immunological responses after 6 months of antiretroviral treatment in adults with HIV-1 infection in sub-Saharan Africa.

De Luca A, Marazzi MC, Mancinelli S, Ceffa S, Altan AM, Buonomo E, Prosperi MC, Pedruzzi B, Noorjehan AM, Scarcella P, Liotta G, Palombi L.

J Acquir Immune Defic Syndr. 2012 Mar 1;59(3):236-44. doi: 10.1097/QAI.0b013e31824276e9.

PMID:
22327246
[PubMed - indexed for MEDLINE]
16.

CD4 cell count and viral load monitoring in patients undergoing antiretroviral therapy in Uganda: cost effectiveness study.

Kahn JG, Marseille E, Moore D, Bunnell R, Were W, Degerman R, Tappero JW, Ekwaru P, Kaharuza F, Mermin J.

BMJ. 2011 Nov 9;343:d6884. doi: 10.1136/bmj.d6884.

PMID:
22074713
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

The clinical and economic impact of genotype testing at first-line antiretroviral therapy failure for HIV-infected patients in South Africa.

Levison JH, Wood R, Scott CA, Ciaranello AL, Martinson NA, Rusu C, Losina E, Freedberg KA, Walensky RP.

Clin Infect Dis. 2013 Feb;56(4):587-97. doi: 10.1093/cid/cis887. Epub 2012 Oct 19.

PMID:
23087386
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Cost effectiveness of darunavir/ritonavir in highly treatment-experienced, HIV-1-infected adults in the USA.

Mauskopf J, Brogan A, Martin S, Smets E.

Pharmacoeconomics. 2010;28 Suppl 1:83-105. doi: 10.2165/11587470-000000000-00000.

PMID:
21182346
[PubMed - indexed for MEDLINE]
19.

Cost effectiveness analysis of clinically driven versus routine laboratory monitoring of antiretroviral therapy in Uganda and Zimbabwe.

Medina Lara A, Kigozi J, Amurwon J, Muchabaiwa L, Nyanzi Wakaholi B, Mujica Mota RE, Walker AS, Kasirye R, Ssali F, Reid A, Grosskurth H, Babiker AG, Kityo C, Katabira E, Munderi P, Mugyenyi P, Hakim J, Darbyshire J, Gibb DM, Gilks CF; DART Trial Team.

PLoS One. 2012;7(4):e33672. doi: 10.1371/journal.pone.0033672. Epub 2012 Apr 24.

PMID:
22545079
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Developments in CD4 and viral load monitoring in resource-limited settings.

Rowley CF.

Clin Infect Dis. 2014 Feb;58(3):407-12. doi: 10.1093/cid/cit733. Epub 2013 Nov 11. Review.

PMID:
24218101
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk